| |
Lamivudine
Because it is a fixed-dose combination, imunaid should not be prescribed
for patients requiring dosage adjustment, such as those with low body weight (<50
kg)
Nevirapine
imunaid should be discountinued if patients
experience severe rash or a rash accompanied by constitutional findings ( see
Warnings and Precautions). Patients experiencing mild to moderate rash during
the 14 day lead-in period of 200 mg/ day should not have their nevirapine dose
increased or start therapy with imunaid until the rash has resolved (see Warnings
and Precautions).
imunaid administration should be interrupted in patients
experiencing moderate or severe liver function tests abnormalities (excluding
GGT), until the liver function test elevations have returned to baseline. Nevirapine
(using Nevimune tablets) may then be restarted at 200mg per day. Increasing the
daily dose to 200 mg twice daily (using imunaid) should be done with caution, after extended observation. Nevirapine should be permanently discontinued if moderate
or severe liver function test abnormalities recur ( see Warnings and Precautions).
Patients who interrupt nevirapine dosing more than 7 days should restart
the recommended dosing, using one 200mg Nevimune tablet daily for the first 14
days (lead-in) in combination with the other antiretrovirals, followed by 200
mg twice daily using imunaid in the absence of any signs of hypersensitivity.
No data are available to recommend a dosage of nevirapine in patients
with hepatic dysfunction, renal insufficiency or undergoing dialysis. | |
